GlycoEra Welcomes Andrea Matthews as New Chief Business Officer for Growth Acceleration

GlycoEra Appoints Andrea Matthews as Chief Business Officer

In a significant strategic move aimed at enhancing its growth trajectory, GlycoEra AG, a pioneering biotechnology firm focused on developing cutting-edge extracellular protein degraders for autoimmune diseases, has appointed Andrea Matthews as its new Chief Business Officer. The decision was officially announced on September 16, 2026, and is viewed as a pivotal step in positioning the company for the next phase of its development.

Leadership Vision

Ganesh Kaundinya, Ph.D., the CEO of GlycoEra, expressed enthusiasm over Matthews' joining, stating, “We are delighted to welcome Andrea to GlycoEra's leadership team.” This sentiment reflects the confidence the company has in Matthews' extensive strategic expertise within public biotech firms. Her impressive track record includes facilitating significant transactions and propelling companies forward in their scientific endeavors. According to Kaundinya, her insights will be invaluable as GlycoEra strives to widen its pipeline and operational reach, ultimately aiming to deliver transformative medicines to patients.

Focus on Innovation

Matthews shared her excitement about her new role, noting, “GlycoEra has built a highly differentiated protein degrader platform that possesses the potential to deliver treatments with exceptional speed and selectivity.” In particular, she highlighted the company’s lead program, GE8820, which targets conditions such as pemphigus vulgaris and primary membranous nephropathy. “Helping these patients is only the beginning. I am thrilled to join GlycoEra at this transformative time and look forward to collaborating with the team to advance GE8820, expand our pipeline, and tap into the wider possibilities of our platform for patient benefit,” she added.

A Proven Track Record

Before her role at GlycoEra, Matthews was the Chief Business Officer at Astria Therapeutics, where she spearheaded corporate strategy, business development, investor relations, and patient advocacy. Notably, during her tenure, she played a key role in executing Astria’s notable $920 million acquisition by BioCryst Pharmaceuticals. Prior to this, she held senior roles at Catabasis Pharmaceuticals and Selventa, contributing to significant capital raises exceeding $700 million, including an IPO, mergers, and licensing deals throughout her over 20-year career in the biotechnology sector.

Academic Credentials

Andrea Matthews holds an MBA from the prestigious MIT Sloan School of Management and a degree in Biochemistry and Molecular Biology from Boston University. Her academic background complements her extensive professional experience and positions her as a strategic leader well-equipped to navigate the complexities of the biotechnology landscape.

About GlycoEra

GlycoEra AG is committed to transforming the treatment of autoimmune diseases through advanced protein degraders. Utilizing the principles of glycoengineering, the company works to precisely target and eliminate disease-causing proteins from the body. With its headquarters located in Wädenswil, Switzerland, and additional operations in Newton, Massachusetts, GlycoEra continues to cultivate its innovative pipeline of therapies aimed at addressing autoimmune and inflammatory diseases.

For more information on GlycoEra and its leadership team, please visit GlycoEra's official website or connect with us on LinkedIn.